Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques

Vaccine

Volumn 24, Issue 42-43, 2006, Pages 6493-6502

  Stewart, V Ann ^a   Walsh, Douglas S ^a   McGrath, Shannon M ^a   Kester, Kent E ^a   Cummings, James F ^a   Voss, Gerald ^b   Delchambre, Martine ^b   Garçon, Nathalie ^b   Cohen, Joe D ^b   Heppner Jr , D Gray ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; Cell mediated immunogenicity; Delayed type hypersensitivity (DTH); Malaria; RTS,S; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PARASITE ANTIGEN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOPSY; CELL INFILTRATION; CHRONOTHERAPY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; FEMALE; FOLLOW UP; HISTOLOGY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LOW DRUG DOSE; MACACA; MALARIA FALCIPARUM; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SKIN INDURATION; SKIN TEST; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; ERYTHEMA; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; NEUTROPHIL INFILTRATION; PLASMODIUM FALCIPARUM; SKIN; SKIN TESTS;

EID: 33749452426     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.035     Document Type: Article

References (36)

1. Olliaro P., Taylor W.R., and Rigal J. Controlling malaria: challenges and solutions. Trop Med Int Health 6 (2001) 922-927
2. Guerin P.J., Olliaro P., Nosten F., Druilhe P., Laxminarayan R., Binka F., et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2 (2002) 564-573
3. Snow R.W., and Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 52 (2002) 235-264
4. Hay S.I., Were E.C., Renshaw M., Noor A.M., Ochola S.A., Olusanmi I., et al. Forecasting, warning, and detection of malaria epidemics: a case study. Lancet 361 (2003) 1705-1706
5. Ariey F., and Robert V. The puzzling links between malaria transmission and drug resistance. Trends Parasitol 19 (2003) 158-160
6. Ballou W.R., Kester K.E., and Heppner D.G. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. Chem Immunol 80 (2002) 253-261
7. Heppner Jr. D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 (2005) 2243-2250
8. Ballou W.R. Malaria vaccines in development. Expert Opin Emerg Drugs 10 (2005) 489-503
9. Garcon N., Heppner D.G., and Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2 (2003) 231-238
10. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (1997) 86-91
11. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 (2001) 640-647
12. Ballou W.R., Arevalo-Herrera M., Carucci D., Richie T.L., Corradin G., Diggs C., et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71 (2004) 239-247
13. Stoute J.A., Heppner D.G., Mason C.J., Siangla J., Opollo M.O., Kester K.E., et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am J Trop Med Hyg 75 (2006) 166-170
14. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 (1999) 1656-1664
15. Pinder M., Reece W.H.H., Plebanski M., Akinwunmi P., Flanagan K.L., Lee E.A.M., et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 135 (2004) 286-293
16. Sun P.F., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma. J Immunol 171 (2003) 6961-6967
17. Doherty J.F., Pinder M., Tornieporth N., Carton C., Vigneron L., Milligan P., et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 61 (1999) 865-868
18. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 (1998) 1139-1144
19. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
20. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
21. Stewart V.A., McGrath S.M., Davis S., Hess A.S., Ware L.A., Kester K.E., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24 (2006) 6483-6492
22. Walsh D.S., Pichyangkul S., Gettayacamin M., Tongtawe P., Siegrist C.A., Hansukjariya P., et al. Safety and immunogenicity of RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys. Am J Trop Med Hyg 70 (2004) 499-509
23. Pichyangkul S., Gettayacamin M., Miller R.S., Lyon J.A., Angov E., Tongtawe P., et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22 (2004) 3831-3840
24. Walsh D.S., Looareesuwan S., Vaniganonta S., Viravan C., and Webster H.K. Cutaneous delayed-type hypersensitivity responsiveness in patients during and after Plasmodium falciparum and Plasmodium vivax infections. Clin Immunol Immunopathol 77 (1995) 89-94
25. Sitz K.V., Loomis-Price L.D., Ratto-Kim S., Kenner J.R., Sau P., Eckels K.H., et al. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J Infect Dis 176 (1997) 1085-1089
26. Yang D.M., Rogers M.V., and Liew F.Y. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology 72 (1991) 3-9
27. Cabrera E.J., Speer C.A., Schenkel R.H., Barr M.L., and Silverman P.H. Delayed dermal hypersensitivity in rhesus monkeys (Macaca mulatta) immunized against Plasmodium knowlesi. Z Parasitenkd 50 (1976) 31-42
28. Kublin J.G., Lowitt M.H., Hamilton R.G., Oliveira G.A., Nardin E.H., Nussenzweig R.S., et al. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20 (2002) 1853-1861
29. Putnak J.R., Coller B., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 (2005) 4442-4452
30. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164 (2000) 1617-1624
31. Kolodny N., Kitov S., Vassell M.A., Miller V.L., Ware L.A., Fegeding K., et al. Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Escherichia coli. J Chromatogr B Biomed Sci Appl 762 (2001) 77-86
32. Silber A., Newman W., Reimann K.A., Hendricks E., Walsh D., and Ringler D.J. Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. Lab Invest 70 (1994) 163-175
33. Silber A., Newman W., Sasseville V.G., Pauley D., Beall D., Walsh D.G., et al. Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1. J Clin Invest 93 (1994) 1554-1563
34. Ringler D., Hancock W., King N., and Murphy G. Characterization of nonhuman primate epidermal and dermal dendritic cells with monoclonal antibodies. Lab Invest 56 (1987) 313-320
35. Flynn J.L., Capuano S.V., Croix D., Pawar S., Myers A., Zinovik A., et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) 83 (2003) 116-118
36. http://www.clinicaltrials.gov/ct/show/NCT00075049. Accessed 14 May 2006.